Cargando…

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ

Although ductal carcinoma in situ (DCIS) is a non-obligate precursor to ipsilateral invasive breast cancer (iIBC), most DCIS lesions remain indolent. Hence, overdiagnosis and overtreatment of DCIS is a major concern. There is an urgent need for prognostic markers that can distinguish harmless from p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almekinders, Mathilde M. M., Schaapveld, Michael, Thijssen, Bram, Visser, Lindy L., Bismeijer, Tycho, Sanders, Joyce, Isnaldi, Edoardo, Hofland, Ingrid, Mertz, Marjolijn, Wessels, Lodewyk F. A., Broeks, Annegien, Hooijberg, Erik, Zwart, Wilbert, Lips, Esther H., Desmedt, Christine, Wesseling, Jelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985299/ https://www.ncbi.nlm.nih.gov/pubmed/33753731 http://dx.doi.org/10.1038/s41523-021-00232-w

Ejemplares similares

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
por: Almekinders, Mathilde M., et al.
Publicado: (2022)

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
por: Kim, Yongsoo, et al.
Publicado: (2019)

Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis
por: Bismeijer, Tycho, et al.
Publicado: (2018)

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
por: Lefrère, Hanne, et al.
Publicado: (2023)

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients
por: Ragusi, Max A.A., et al.
Publicado: (2021)

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast
por: van Seijen, Maartje, et al.
Publicado: (2021)

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women
por: Elshof, Lotte E., et al.
Publicado: (2016)

Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2014)

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance
por: Hoogstraat, Marlous, et al.
Publicado: (2022)

A multilevel pan-cancer map links gene mutations to cancer hallmarks
por: Knijnenburg, Theo A., et al.
Publicado: (2015)

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
por: Zwart, Wilbert, et al.
Publicado: (2013)

Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases
por: Margarido, Andreia S., et al.
Publicado: (2022)

Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Targeting the RB-E2F pathway in breast cancer
por: Johnson, Jackie, et al.
Publicado: (2016)

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
por: Lips, Esther H, et al.
Publicado: (2011)

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
por: Lips, Esther H., et al.
Publicado: (2015)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study
por: Mannu, Gurdeep S., et al.
Publicado: (2019)

Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping
por: Rontogianni, Stamatia, et al.
Publicado: (2019)

Approximating multivariate posterior distribution functions from Monte Carlo samples for sequential Bayesian inference
por: Thijssen, Bram, et al.
Publicado: (2020)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
por: Van Bockstal, Mieke R., et al.
Publicado: (2020)

Keratinocytic epidermal nevus with ipsilateral breast hypoplasia()()
por: Chen, Eric, et al.
Publicado: (2019)

Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer
por: Giardiello, Daniele, et al.
Publicado: (2020)

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review
por: Alaeikhanehshir, Sena, et al.
Publicado: (2020)

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome
por: Schrijver, Willemijne, et al.
Publicado: (2018)

The spectrum of ATM missense variants and their contribution to contralateral breast cancer
por: Broeks, Annegien, et al.
Publicado: (2007)

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2(+) breast cancer
por: Debets, Donna O., et al.
Publicado: (2023)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases
por: Vollebergh, Marieke A., et al.
Publicado: (2014)

Advanced right lung adenocarcinoma with ipsilateral breast metastasis
por: Liam, Chong-Kin, et al.
Publicado: (2013)

Becker Nevus Syndrome Presented with Ipsilateral Breast Hypoplasia
por: Pektas, Suzan Demir, et al.
Publicado: (2014)

Ipsilateral Lymphadenopathy, COVID-19 Vaccination and Breast Cancer
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Proteogenomics decodes the evolution of human ipsilateral breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2023)

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors
por: Bronsveld, Heleen K., et al.
Publicado: (2018)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

Fibromatosis (desmoid tumor) of the breast mimicking a case of ipsilateral metachronous breast cancer
por: Povoski, Stephen P, et al.
Publicado: (2006)

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
por: Gosset, Marie, et al.
Publicado: (2016)

BRCA1‐like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
por: Severson, Tesa M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lvu6fat6r3m8sv3sganau2ukv7